

# Treatment of high risk testicular tumour with high dose chemotherapy with peripheral blood stem cells

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 20/04/2016	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr PM Wilkinson

### Contact details

Clinical Oncology  
Christie Hospital NHS Trust  
Wilmslow Road  
Withington  
Manchester  
United Kingdom  
M20 4BX  
+44 0161 446 3261  
Peter.Wilkinson@christie-tr.nwest.nhs.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0063044257

# Study information

## Scientific Title

Treatment of high risk testicular tumour with high dose chemotherapy with peripheral blood stem cells

## Study objectives

To assess the efficacy of high dose chemotherapy with peripheral blood stem cells to see if the response rate is improved compared to conventional therapy.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Not Specified

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cancer: Testicular

## Interventions

High dose chemotherapy with peripheral blood stem cells vs no high dose

## Intervention Type

Other

## Phase

Not Specified

**Primary outcome measure**

1. Time to white cell and platelet recovery
2. Confirmation of response
3. Assessment of toxicity by standard World Health Organisation (WHO) grades

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/05/1994

**Completion date**

31/12/2008

## Eligibility

**Key inclusion criteria**

1. Patients with histological proven non-seminomatous germ cell tumours
2. High risk factors as defined by MRC prognostic group

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Male

**Target number of participants**

6

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/05/1994

**Date of final enrolment**

31/12/2008

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**Clinical Oncology**  
Manchester  
United Kingdom  
M20 4BX

## **Sponsor information**

**Organisation**  
Department of Health (UK)

**Sponsor details**  
Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

**Sponsor type**  
Government

**Website**  
<http://www.doh.gov.uk>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
Christie Hospital NHS Trust (UK)

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration